Cardiovascular damage in patients with systemic scleroderma.

Authors

  • GUTAN Inesa Instituția medico- sanitară publică Institutul de Cardiologie
  • DODU Stela Instituția medico- sanitară publică Institutul de Cardiologie
  • PANFILE Elena Instituția medico- sanitară publică Institutul de Cardiologie
  • LISII Dorin Instituția medico- sanitară publică Institutul de Cardiologie
  • CIOBANU Nicolae Instituția medico- sanitară publică Institutul de Cardiologie
  • MAZUR-NICORICI Lucia Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”
  • VETRILA Snejana Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”
  • MAZUR Minodora Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.26

Keywords:

systemic scleroderma, vasospastic disorders, cardiovascular damage

Abstract

Systemic sclerosis is a generalized disease of the connective tissue characterized by the expression of pathological manifestations of the skin, musculoskeletal system with damage to the heart, lungs, kidneys, gastrointestinal tract and diffuse vasospastic disorders caused by damage to the connective tissue and the predominance of fibrosis the type of obliterating microangiopathy. Cardiovascular manifestations occur in about 10% of patients with SSc, being an important predictor of patient mortality and often associated with an unfavorable prognosis.

Author Biographies

GUTAN Inesa, Instituția medico- sanitară publică Institutul de Cardiologie

medic cardiolog

DODU Stela, Instituția medico- sanitară publică Institutul de Cardiologie

medic cardiolog

PANFILE Elena, Instituția medico- sanitară publică Institutul de Cardiologie

dr. șt. med

LISII Dorin, Instituția medico- sanitară publică Institutul de Cardiologie

dr. șt. med., conf. cercetător

CIOBANU Nicolae, Instituția medico- sanitară publică Institutul de Cardiologie

dr. hab. șt. med., prof. cercetător

MAZUR-NICORICI Lucia, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

a, dr. hab. șt. med., prof. univ

VETRILA Snejana, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr. șt. med., conf. univ

MAZUR Minodora, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr. hab. șt. med., prof. univ

References

Groppa L. et al. Protocol clinic național: Sclerodermia sistemică la adult., 2018; PCN-90: 6.

Careta M., Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol., 2015; 90(1):62-73.

Rongioletti F., Ferreli C., Atzori L., et. al. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol., 2018; 153:208

Bergamasco A., Hartmann N., Wallace L., et al. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol., 2019; 11:257-273.

Medsger T., Masi A. The epidemiology of systemic sclerosis (scleroderma). Ann Intern Med., 1971; 74:714-21.

Heine J. Uber ein eigenartiges Krankheitsbild von deiffuser Sklerosis der haut and innerer organe. Virchows Arch., 1926; 262:1.

Čolić J., Matucci C. et al. Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question! J Scleroderma Relat Disord., 2020; 5: 6-20.

Sgonc R., Gruschwitz M.S., Boeck G. et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody‐dependent cell‐mediated cytotoxicity via CD95. Arthritis Rheum., 2000; 43: 2550–62.

Katsumoto T., Whitfield M. and Connolly M. The pathogenesis of systemic sclerosis. Annual Review of Pathology: Mechanisms of Disease., 2011; 6: 509–537.

Desai C., Lee D., Shah S. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol., 2011; 23(6):545.

Tyndall A., Bannert B., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis., 2010; 69:1809–1815.

Roberts N., Cabeen W. Jr, Moss J. et al. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med., 1981; 94:38–40.

Gowda R., Khan I. et al. Scleroderma pericardial disease presented with a large pericardial effusion—a case report. Angiology., 2001; 52:59-62.

Morrisroe K., Stevens W. et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening program. Arthritis Res Ther., 2017; 19(1):42.

Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest, 2013;144(4):1346-1356.

De Groote P., Gressin V., Hachulla E., et al; ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis., 2008; 67(1):31-36.

Cannarile F., Valentini V., Mirabelli G., et al. Cardiovascular disease in systemic sclerosis. Ann Transl Med. 2015;3(1):8. doi:10.3978/j.issn.2305-5839.2014.12.12).

Ngian G., Sahhar J. et al. Cardiovascular disease in systemic sclerosis. Ann Rheum Dis., 2015 Dec; 71(12):1980-3.

Sponga S., Basso C., Ruffatti A., Gerosa G. Systemic sclerosis and aortic valve stenosis: therapeutic implications in two cases of aortic valve replacement. J Cardiovasc Med (Hagerstown)., 2009; 10:560–562.

Published

2022-04-08